Owkin Partners with Boehringer Ingelheim for AI-Driven Cancer and Immunology Drug Discovery

Biotech company Owkin has signed a strategic agreement with pharmaceutical giant Boehringer Ingelheim to leverage artificial intelligence for accelerating the development of treatments targeting cancer and immunological diseases.

2 Sept, 14:47 — 2 Sept, 14:47

Post Share

Sources

Showing 1 of 1 sources

ReutersVery High1d ago

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology - Reuters

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology Reuters

Read full article →

Owkin Partners with Boehringer Ingelheim for AI-Driven Cancer and Immunology Drug Discovery

Sources

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology - Reuters

Related Stories

OpenAI Unveils Advanced GPT-6 Astra Model Amid Growing AI Safety Concerns

Nvidia Sets October Release Date for New RTX Spark AI PCs

Nvidia to Acquire Hugging Face for $13 Billion

ISRO Successfully Launches India’s First Geosynchronous Imaging Satellite